Molbio Diagnostics IPO debuts with strong listing amid GMP cues
Molbio Diagnostics listed on NSE and BSE on Aug 17, 2026, after a robust 70.26x subscription. The stock opened around ₹980, signaling a premium to the issue price of ₹807.
Key takeaways
- Molbio Diagnostics completed a Rs 940 crore IPO, with a fresh issue of Rs 200 crore and an offer for sale of Rs 739.70 crore.
- The issue was priced at ₹768–₹807 per share and subscribed 70.26 times overall, with QIBs leading at 186.39 times.
- The stock opened at ₹980 on both exchanges, implying a listing premium above the issue price of ₹807.
- Proceeds are targeted at expanding infrastructure, R&D facilities, and manufacturing capacity, including a Centre of Excellence.
- Molbio is known for the Truenat platform and has backing from Temasek and Motilal Oswal Private Equity.
What Happened
Molbio Diagnostics began trading on the National Stock Exchange and Bombay Stock Exchange on August 17, 2026, after finalising allotments on August 13. The IPO size was Rs 940 crore, consisting of a fresh issue of Rs 200 crore and an offer for sale of Rs 739.70 crore. The issue was priced in a band of ₹768–₹807 per share. Demand was intense, with overall subscriptions totaling 70.26 times; QIBs subscribed at 186.39 times, NIIs at 49.80 times, and retail investors at 12.96 times. Earlier, Molbio raised Rs 281.5 crore from anchor investors ahead of the listing, allotting 34.87 lakh equity shares at ₹807 per share to 33 anchor investors. Grey-market data suggested a premium around ₹120, implying a potential listing price near ₹927, about 14.87% above the upper band. The stock opened at ₹980 on both exchanges, marking an estimated 21% gain from the issue price.
Why It Matters
The listing follows a strong capital-raising exercise that supports Molbio’s expansion plans, including infrastructure build-out, a Centre of Excellence, and manufacturing capacity upgrades. The use of proceeds is earmarked for capital expenditure and general corporate purposes, with a multi-pronged strategy to scale its Truenat platform and related diagnostics capabilities. The debut outperformed grey-market expectations and reflects sustained investor demand for the company’s diagnostic solutions and its backing by institutional investors.
Background
Molbio Diagnostics was established in October 2000 as a global molecular diagnostics company focused on rapid diagnostic solutions for infectious and non-communicable diseases. It is best known for its Truenat platform, a portable, battery-powered PCR-based system capable of delivering results within an hour. The company operates across more than 30 diseases through 43 diagnostic assays and has diversified into radiology, digital pathology, and breast health screening via subsidiaries and partnerships.
Key Facts
- IPO size: Rs 940 crore (fresh issue Rs 200 crore; OFS Rs 739.70 crore)
- IPO price band: ₹768–₹807 per share
- Anchor investors raised: Rs 281.5 crore; 34.87 lakh shares allotted at ₹807
- Subscription: 70.26x overall; QIBs 186.39x; NIIs 49.80x; retail 12.96x
- Listing price: around ₹927 based on grey market, opening price ₹980
- Use of proceeds: capex and R&D facility development, Centre of Excellence, manufacturing plant upgrades
- Founding background: established October 2000; Truenat platform;
- Key backers: Temasek and Motilal Oswal Private Equity
Sources reviewed
Project Chintan independently synthesized and analyzed information cross-checked across the sources listed above.
Related stories
Dhoot Transmission IPO listing today with 30% GMP signal
Madhusudan Kela portfolio shows 7 CY26 gainers up to 135%
Navy sailor, wife and two children found dead in Mumbai home; police probe
